CLDN18 — gene · CancerIndex

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CLDN18 positive2
CAPOX Regimen + ZolbetuximabCombination	Gastric Adenocarcinoma	Predictive	A	Supports Sensitivity Response	5	submitted	EID12216 In the phase 3 GLOW trial (NCT03653507), 507 patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma were randomized 1:1 to receive either zolbetuximab combined with CAPOX … (full text at CIViC) PMID 37524953 · Shah et al., 2023 · Open in CIViC	civic
FOLFOX-6 Regimen + ZolbetuximabCombination	Gastric Adenocarcinoma	Predictive	A	Supports Sensitivity Response	4	submitted	EID12215 In the phase 3 SPOTLIGHT trial (NCT03504397), 565 patients with gastroesophageal junction adenocarcinoma were randomized to receive either zolbetuximab combined with mFOLFOX6 (n=283) or placebo with m…

Cohorts

Alteration frequency by cohort (2)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Pediatric Low-Grade Glioma (CTF, Acta Neuropathol 2021) lgg_ctf_synodos_2025	Diffuse Glioma	Ssm	1	31

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.